News
PHCUF
6.63
NaN%
--
FDA Move to Ease Regulatory Pathway Seen as Catalyst for Photocure’s Bladder Cancer Technology
TipRanks · 08/14 16:21
Photocure Study Finds Blue Light Cystoscopy Boosts Bladder Cancer Detection Without Raising Costs
TipRanks · 08/11 07:11
Photocure Board Members Boost Shareholdings, Signaling Confidence in Uro-Oncology Strategy
TipRanks · 08/07 16:37
Photocure escalates arbitration in Cevira milestone dispute with Asieris
TipRanks · 08/04 06:38
Photocure ASA Earnings Call Signals Growth-Driven Strategy
TipRanks · 07/31 00:24
Photocure Grants Executive Share Options to Align Leadership With Shareholder Value
TipRanks · 07/29 20:02
Photocure lifts growth outlook as bladder cancer diagnostics strategy accelerates
TipRanks · 07/29 06:37
Photocure to Present Q2 2026 Results in Live Investor Webcast
TipRanks · 07/22 12:39
Photocure Grants Employee Share Options Under Long-Term Incentive Plan
TipRanks · 07/14 06:35
Photocure CFO Erik Dahl to Retire, CEO Named Acting Successor
TipRanks · 06/30 14:03
Photocure shareholders approve key resolutions at annual general meeting
TipRanks · 06/26 17:32
Photocure and Artera launch AI-driven bladder cancer diagnostics collaboration
TipRanks · 06/08 16:37
Photocure Calls Fully Virtual Annual General Meeting for 26 June 2026
TipRanks · 06/05 13:04
Photocure’s Blue Light Cystoscopy Data Underscore Clinical Edge and Cost Neutrality
TipRanks · 05/18 15:39
Photocure lifts Q1 revenues on BLC adoption and Cevira milestones
TipRanks · 05/07 05:36
Photocure’s Blue Light Cystoscopy Shown Cost-Effective in New Health Economics Study
TipRanks · 05/04 06:35
Photocure Sets Date and Webcast for First-Quarter 2026 Results
TipRanks · 04/30 08:26
Photocure releases 2025 annual and integrated ESG reports
TipRanks · 04/27 07:31
Photocure Challenges Partner Over Unpaid Cevira Milestone After China Approval
TipRanks · 04/20 15:04
Photocure Sets Out Financial Reporting Calendar for 2025–2026
TipRanks · 04/13 14:35
More
Webull provides a variety of real-time PHCUF stock news. You can receive the latest news about Photocure ASA through multiple platforms. This information may help you make smarter investment decisions.
About PHCUF
Photocure ASA is a Norway-based company active in the pharmaceutical industry. The Company is focused on developing and improving photodynamic technology and owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. Based on the Photocure Technology platform, Photocure has developed and commercialized Hexvix (Hyperthermic IntraVEsical Chemotherapy) and Cysview (hexaminolevulinate HCL) for use in bladder cancer. The Company’s activities are divided into two business segments: The Commercial Franchise and The Development Portfolio. The Commercial Franchise segment includes Hexvix/Cysview by geography (U.S. and Europe) and other sales (partners and other products including sales revenues for Hivec). The Development Portfolio segment includes development of pipeline products.